Mixed trend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Oct 7 · below the Ichimoku cloud · RSI 48 · MACD below its signal · at its 52-week low
| 0.2000 | 52-week high | +199900.00% |
| 0.0550 | Previous month high | +54900.00% |
| 0.0300 | Previous week high | +29900.00% |
| 0.000100 | Price now | |
| 0.000100 | R3 (classic) | −0.00% |
| 0.000100 | R2 (classic) | −0.00% |
| 0.000100 | R1 (classic) | −0.00% |
| 0.000100 | Pivot | −0.00% |
| 0.000100 | S1 (classic) | −0.00% |
| 0.000100 | S2 (classic) | −0.00% |
| 0.000100 | S3 (classic) | −0.00% |
| 0.000100 | Previous day high | −0.00% |
| 0.000100 | Previous day low | −0.00% |
| 0.000100 | Previous week low | −0.00% |
| 0.000100 | Previous month low | −0.00% |
| 0.000100 | 52-week low | −0.00% |
None of the 29 investors followed here reported a position in VAXX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VAXX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for VAXX.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -66.7 | 100.0 | 0.0 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −66.7% | ||
| 2025 | -96.0 | -50.0 | 500.0 | 2400.0 | -33.3 | -99.0 | 0.0 | 43900.0 | -54.5 | -99.5 | 19900.0 | -98.5 | −94.0% |
| 2024 | -16.5 | 20.4 | -16.1 | -82.9 | -36.2 | 218.6 | -84.0 | -97.5 | -80.0 | 900.0 | -95.0 | 4900.0 | −99.4% |
| 2023 | 185.7 | -41.3 | -3.4 | -6.2 | -16.4 | 41.6 | 6.7 | -24.9 | -32.2 | -16.1 | -26.2 | 0.2 | −39.3% |
| 2022 | 6.6 | -16.4 | -14.0 | 61.5 | -39.2 | -62.8 | 11.5 | 36.0 | -16.8 | -33.3 | 98.5 | -46.6 | −75.0% |
| 2021 | -54.9 | −54.9% |
No analyst coverage for this instrument.
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
No recent headlines.